Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: Model development and evaluation and derivation of analytical solutions for ka and Fa

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 391-399

  Usansky, Helen H ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ACICLOVIR; ALPRENOLOL; AMINOPHENAZONE; ATENOLOL; CHLOROTHIAZIDE; CHLORPROMAZINE; CIMETIDINE; CLONIDINE; CORTICOSTERONE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DILTIAZEM; DOXORUBICIN; FUROSEMIDE; GANCICLOVIR; GLYCINE; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; IBUPROFEN; IMIPRAMINE; INDOMETACIN; LABETALOL; MANNITOL; MELOXICAM; METHOTREXATE; METOPROLOL; UNINDEXED DRUG;

ARTICLE; BLOOD LEVEL; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; ERROR; HUMAN; HUMAN CELL; KINETICS; MATHEMATICAL MODEL; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS;

EID: 23044469809     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.076182     Document Type: Article

References (53)

1. Amidon GL, Sinko PJ, and Fleisher D (1988) Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res (NY) 5:651-654.
2. Benet LZ, Massoud N, and Gambertoglio JG (1984) Pharmacokinetic Basis for Drug Treatment, Raven Press, New York, NY.
3. Blanchard J and Sawers SJ (1983) Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm 11:109-126.
4. Borgstrom L, Nyberg L, Jonsson S, Lindberg C, and Paulson J (1989) Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br J Clin Pharmacol 27:49-56.
5. Caldwell GW, Easlick SM, Gunnet J, Masucci JA, and Demarest K (1998) In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom 33:607-614.
6. Ciraulo DA, Barnhill JG, and Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509-518.
7. Collett A, Sims E, Walker D, He YL, Ayrton J, Rowland M, and Warhurst G (1996) Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res (NY) 13:216-221.
8. Dahl SG and Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437-448.
9. Davenport HW (1982) Physiology of the Digestive Tract, 5th ed, Year Book Medical Publishers, Inc., Chicago, IL.
10. Dressman JB, Fleisher D, and Amidon GL (1984) Physicochemical model for dosedependent drug absorption. J Pharm Sci 73:1274-1279.
11. Eagling VA, Profit L, and Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552.
12. Garceau Y, Davis I, and Hasegawa J (1978) Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid and p-hydroxypropranolol in human plasma and urine. J Pharm Sci 67:826-831.
13. Gilman AG, Rall TW, Nies AS, and Taylor P (1990) Goodman & Gilman's The Pharmacological Basis of Therapeutics, Pergamon Press, New York.
14. Glynn SL and Yazdanian M (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 87:306-310.
15. Hermann P, Rodger SD, Remones G, Thenot JP, London DR, and Morselli PL (1983) Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol 24:349-352.
16. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, and Langguth P (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89:63-75.
17. Ho NF and Higuchi WI (1974) Theoretical model studies of intestinal drug absorption. IV. Bile acid transport at premicellar concentrations across diffusion layermembrane barrier. J Pharm Sci 63:686-690.
18. Holford NH (1986) Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 11:483-504.
19. Kulkarni A, Han Y, and Hopfinger AJ (2002) Predicting Caco-2 cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. J Chem Inf Comput Sci 42:331-342.
20. Lee EJ, Williams K, Day R, Graham G, and Champion D (1985) Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19:669-674.
21. Leo A, Hansch C, and Elkins D (1971) Partitioning coefficients and their uses. Chem Rev 71:525-616.
22. Lobenberg R and Amidon GL (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12.
23. Lowenthal DT, Matzek KM, and MacGregor TR (1988) Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 14:287-310.
24. Mandagere AK, Thompson TN, and Hwang KK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311.
25. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, and Streeter AJ (2001) Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods 46:51-55.
26. Martinez MN and Amidon GL (2002) A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42:620-643.
27. Mason WD, Covinsky JO, Valentine JL, Kelly KL, Weddle OH, and Martz BL (1976) Comparative plasma concentrations of quinidine following administration of one intramuscular and three oral formulations to 13 human subjects. J Pharm Sci 65:1325-1329.
28. McGourty JC, Silas JH, Fleming JJ, McBurney A, and Ward JW (1985) Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther 38:409-413.
29. McTavish D and Sorkin EM (1989) Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 38:19-76.
30. Murakami H, Takanaga H, Matsuo H, Ohtani H, and Sawada Y (2000) Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol 279:H1022-H1028.
31. Oberbauer R, Krivanek P, and Turnheim K (1993) Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet 24:428-434.
32. Pade V and Stavchansky S (1998) Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci 87:1604-1607.
33. Poulin P, Schoenlein K, and Theil FP (2001) Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
34. Poulin P and Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
35. Rowland M and Tozer TN (1995) Clinical Pharmacokinetics: Concepts and Applications, 3rd ed, Williams & Wilkins, Media, PA.
36. Rudorfer MV, Lane EA, Chang WH, Zhang MD, and Potter WZ (1984) Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 17:433-440.
37. Sabanathan K, Castleden CM, Adam HK, Ryan J, and Fitzsimons TJ (1987) A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharmacol 32:53-60.
38. Shah MV, Audus KL, and Borchardt RT (1989) The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm Res (NY) 6:624-627.
39. Sinko PJ, Kunta JR, Usansky HH, and Perry BA (2004) Differentiation of gut and hepatic first-pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther 310:359-366.
40. Sinko PJ, Leesman GD, and Amidon GL (1991) Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (NY) 8:979-988.
41. Sinko PJ, Leesman GD, and Amidon GL (1993) Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications. Pharm Res (NY) 10:271-275.
42. Snyder WS, Cook MJ, Nasset ES, Karhuausen LR, Howells GP, and Tipton IH (1975) Report of the Task Group on Reference Man, Pergamon, New York.
43. Sosogi A, Gao F, Tomimatsu T, Hirata K, and Horie T (2003) Effects of non-steroidal anti-inflammatory drugs on the methotrexate transport in rat small intestine. Scand J Gastroenterol 38:43-49.
44. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, and Amidon GL (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (NY) 19:1400-1416.
45. Toon S, Davidson EM, Garstang FM, Batra H, Bowes RJ, and Rowland M (1988) The racemic metoprolol H2-antagonist interaction. Clin Pharmacol Ther 43:283-289.
46. Wagner JG (1975) Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Inc., Hamilton, IL.
47. Wagner JG (1993) Pharmacokinetics for the Pharmaceutical Scientist, Technomic Publishing Company, Inc., Lancaster, PA.
48. Yazdanian M (1999) Blood-brain barrier properties of human immunodeficiency virus antiretrovirals. J Pharm Sci 88:950-954.
49. Yazdanian M, Glynn SL, Wright JL, and Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res (NY) 15:1490-1494.
50. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res (NY) 14:763-766.
51. Yu LX and Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.
52. Yu LX, Gatlin L, and Amidon GL (2000) Predicting oral drug absorption in humans, in Transport Processes in Pharmaceutical Systems (Amidon GL, Lee PI, and Topp EM eds) pp 377-409, Marcel Dekker, Inc., New York, NY.
53. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, et al. (2001) Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784.